Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: placebo
Drug: aleglitazar

First Posted Date: 2013-06-06

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 13

Registration Number: NCT01871428

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: aleglitazar
Drug: placebo
Drug: metformin

First Posted Date: 2013-06-06

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 7

Registration Number: NCT01871415

A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Lebrikizumab
Drug: Placebo

First Posted Date: 2013-06-04

Last Posted Date: 2017-05-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1068

Registration Number: NCT01868061

Locations: 🇵🇱
NZOZ Lekarze Specjalisci, Wroclaw, Poland
🇸🇰
ZAPA JJ Sro, Levice, Slovakia
🇺🇸
Allergy Consultants PA, Boca Raton, Florida, United States

and more 229 locations

A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Lebrikizumab
Drug: Placebo

First Posted Date: 2013-06-03

Last Posted Date: 2017-05-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1081

Registration Number: NCT01867125

Locations: 🇺🇸
Choc Psf, Amc, Orange, California, United States
🇺🇸
North Bay Clinical Trials, Napa, California, United States
🇺🇸
Bensch Research Associates, Stockton, California, United States

and more 227 locations

A Retrospective, Observational Chart Review of Biologics in Monotherapy Versus the Combination Biologic Plus Methotrexate in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2013-05-31

Last Posted Date: 2015-10-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 476

Registration Number: NCT01866150

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)

Completed

Conditions: Ovarian Cancer

First Posted Date: 2013-05-29

Last Posted Date: 2018-09-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 300

Registration Number: NCT01863693

Locations: 🇬🇧
Queen Alexandra Hospital; Portsmouth Haematology & Oncology Centre, Level B, Portsmouth, United Kingdom
🇬🇧
Royal United Hospital; Oncology Department, Bath, United Kingdom
🇬🇧
Eastborne District General Hospital, Eastbourne, United Kingdom

and more 27 locations

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO5545965
Drug: placebo

First Posted Date: 2013-05-29

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 44

Registration Number: NCT01864226

An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)

Terminated

Conditions: Hepatitis D, Chronic

First Posted Date: 2013-05-23

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 45

Registration Number: NCT01861444

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: Bevacizumab
Drug: Lomustine
Drug: Placebo
Radiation: Radiotherapy
Drug: Temozolomide
Drug: SOC Agent

First Posted Date: 2013-05-23

Last Posted Date: 2018-04-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 296

Registration Number: NCT01860638

Locations: 🇦🇹
Medizinische Universität Graz; Universitätsklinik für Neurologie, Graz, Austria
🇷🇴
Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania
🇦🇹
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria

and more 61 locations

A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab (TCZ)
Drug: Methotrexate (MTX)
Drug: Placebo (PBO)

First Posted Date: 2013-05-17

Last Posted Date: 2017-12-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 718

Registration Number: NCT01855789

Locations: 🇺🇸
Phase Iii Clinical Research, Fall River, Massachusetts, United States
🇺🇸
Fort Smith Rheumatology, PC, Fort Smith, Arkansas, United States
🇺🇸
Joao Nascimento, Bridgeport, Connecticut, United States

and more 151 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy